However, it is noteworthy that discontinuation of anti-CCL-2 therapy can lead to rebound, increasing the liberation of monocytes formerly lodged inside the bone marrow, and thus expediting breast cancer metastasis through the promotion of angiogenesis [71]. The gene discussed is CCL2; the disease is breast carcinoma.